



This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 Nature reviews. Molecular Cell Biology, volume 11 issue 12, 2010, doi: 
10.1038/nrm3012 
  
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
http://www.nature.com/nrm/journal/v11/n12/full/nrm3012.html 
 
MET signalling: principles and functions in development, organ 
regeneration and cancer 
 
Livio Trusolino1, Andrea Bertotti1 & Paolo M. Comoglio1   
 
1Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo, Torino, Italy. 
 
Correspondence to: Livio Trusolino1 Email: livio.trusolino@ircc.it 




The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue remodelling, 
which underlies developmental morphogenesis, wound repair, organ homeostasis and cancer 
metastasis, by integrating growth, survival and migration cues in response to environmental stimuli 
or cell-autonomous perturbations. The versatility of MET-mediated biological responses is 
sustained by qualitative and quantitative signal modulation. Qualitative mechanisms include the 
engagement of dedicated signal transducers and the subcellular compartmentalization of MET 
signalling pathways, whereas quantitative regulation involves MET partnering with adaptor 
amplifiers or being degraded through the shedding of its extracellular domain or through 
intracellular ubiquitylation. Controlled activation of MET signalling can be exploited in regenerative 





Throughout embryogenesis, cells bud off from developing tissues and move outwards to shape 
and pattern the complex architecture of prospective organs1. A similar process occurs in adult life 
during wound healing and tissue repair, when lingering cells migrate into injury sites to recreate the 
pre-existing structures2. The acquisition of cell motility is necessary, but not sufficient, for this 
event. Cells that detach from their neighbours must elude anoikis, a form of apoptotic cell death 
that occurs when cells lose adhesion with the extracellular matrix3. Moreover, migratory cells 
undergo extensive mitotic divisions to produce 'founder populations', which settle in newly forming 
organs during development or colonize worn tissues during repair4, 5. 
The normal phases of embryogenesis and organ regeneration strongly resemble the pathological 
process of tumour invasiveness: similarly to cells at the wound edge, cells at the tumour's leading 
front disrupt intercellular contacts and infiltrate the adjacent surroundings, where they resist anoikis 
and grow before lodging in the blood vessels for systemic dissemination6. This resemblance is not 
simply a biological correlate, it has a common mechanistic basis: cancer cells resurrect the latent 
schemes of cellular reorganization, which are usually confined to embryonic development and 
damaged adult organs, and leverage them to become competent for metastasization7. 
The activities — motility, survival and proliferation — that occur in developing, injured and 
neoplastic tissues embody a biological programme that is defined as 'invasive growth'8. This is 
triggered by extracellular stimuli that regulate the activity of several transcription factors that, in 
turn, modulate the expression of a number of proteins, ranging from cytoskeletal and cell–cell 
junctional components to cell cycle regulators and anti-apoptotic effectors9, 10. One major 
environmental inducer of invasive growth is hepatocyte growth factor (HGF, also known as scatter 
factor), the ligand for the MET tyrosine kinase receptor (also known as the HGF 
receptor)11, 12, 13, 14, 15, 16, 17, 18, 19, 20 (Box 1). MET function is required for various morphogenetic 
events in both embryonic and adult life21, 22 and it drives the malignant progression of several 
different types of tumours23. To do so, MET propagates an intricate system of signalling cascades 
that result in a comprehensive rewiring of gene expression24, 25. 
 
The signal transduction biochemistry of MET includes many idiosyncratic details and only a handful 
of principles that are common to the other tyrosine kinase receptors. Exhaustive information on the 
identities and branches of MET-dependent signalling networks can be found in numerous 
reviews22, 23, 24, 25, 26, 27, 28, 29. Here, as well as presenting some basic principles of MET signalling 
regulation, we consider recent findings that have provided fresh knowledge on this matter at the 
molecular, cellular and animal levels. Specifically, we discuss how the MET pathway is tuned by 
the functional cooperation between various signal transducers, as well as by the receptor's 
subcellular localization and trafficking. We also elaborate on how MET signalling influences 
different organismal functions in normal physiology and disease, a topic that deserves an overall 
reconceptualization. Finally, we examine the causative relationships between individual signalling 
inputs and specific biological outputs in MET-driven processes, and provide our perspective on the 
medical implications of novel therapies that either promote or neutralize MET activity. 
 
MET signalling: pathway components 
HGF is secreted as a single-chain inert precursor and converted into a two-chain functional 
heterodimer by extracellular proteases (Box 1). This growth factor is widely distributed in the 
extracellular matrix of most tissues, where it is sequestered, mainly in its inactive form, by heparin-
like proteoglycans30, 31. Cells of mesenchymal origin are the major source of HGF, which acts in 
a paracrine manner on epithelial cells that express the MET receptor32. During tissue repair and 
cancer invasion, several cytokines that are abundant in the reactive interstitial compartment — for 
example, interleukin-1 and -6, tumour necrosis factor-α and transforming growth factor-β (TGFβ) — 
induce transcriptional upregulation of both HGF (in fibroblasts and resident macrophages) and 
MET (in epithelial cells)33, 34. The inflammatory and tumour stroma also overexpress proteases that 
are involved in pro-HGF activation, such as the plasminogen activation system and matriptase35, 36. 
Thus, biologically competent HGF is not only overproduced but also fully activated. This combined 
transcriptional and post-translational regulation, which leads to optimal MET activation on target 
cells, can be considered as part of a general mechanism of physiological defence to tissue 
damage. 
Following HGF binding, the kinase activity of MET is switched on by receptor dimerization 
and trans-phosphorylation of two 'catalytic' tyrosine residues (Tyr1234 and Tyr1235) within the 
kinase activation loop. The subsequent step is phosphorylation of two additional 'docking' tyrosines 
in the carboxy-terminal tail (Tyr1349 and Tyr1356), and when phosphorylated, these tyrosines act 
as a degenerate motif for the recruitment of many signal-relay molecules37 (Box 1). MET is also a 
substrate for several protein-tyrosine phosphatases (PTPs), including the receptor PTPs density-
enhanced phosphatase 1 (DEP1; also known as PTPRJ) and leukocyte common antigen related 
(LAR; also known as PTPRF)38, 39 and the non-receptor PTPs PTP1B (also known as PTPN1) and 
T cell PTP (TCPTP; also known as PTPN2)40. Such phosphatases oppose MET signals by 
triggering dephosphorylation of either the catalytic tyrosines (in the case of PTP1B and 
TCPTP)40 or the docking tyrosines (in the case of DEP1)38. To date, the MET tyrosine residues that 
are specifically dephosphorylated by LAR have not been identified. 
This is the basic signalling machinery of MET. Further levels of complexity are provided by the 
interaction of MET with different signal modifiers, including scaffolding adaptors, cytoskeletal 
connectors and structurally homologous co-receptors25, 26, 41 (Fig. 1). As a whole, this apparatus 
leads to efficient activation of downstream signal transduction pathways that include the mitogen-
activated protein kinase (MAPK) cascades (extracellular signal-regulated kinase 1 (ERK1) and 
ERK2, Jun amino-terminal kinases (JNKs) and p38), the phosphoinositide 3-kinase–Akt (PI3K–Akt) 
axis, signal transducer and activator of transcription proteins (STATs), and the nuclear factor-κB 
inhibitor-α (IκBα)–nuclear factor-κB (NF-κB) complex22, 25, 42, 43, 44. All of these pathways positively 
control MET-dependent cell proliferation, survival and migration. However, in defined cellular 
contexts, some of these signals can mediate a paradoxical pro-apoptotic, rather than anti-
apoptotic, activity (Box 2). 
 
MET and scaffolding adaptors. The promiscuous docking motif in the C-terminal tail of MET 
binds numerous Src-homology-2 domain (SH2 domain)-containing effectors, such as PI3K37, the 
non-receptor tyrosine kinase Src37, the growth factor receptor-bound protein 2 (GRB2) and SH2 
domain-containing transforming protein (SHC) adaptors37, 45, 46, SHP2 (also known as PTPN11; an 
upstream activator of Src and Ras)46, phospholipase Cγ1 (PLCγ1)37 and the transcription factor 
STAT3 (Refs 47,48). MET also associates with GRB2-associated-binding protein 1 (GAB1), a 
multi-adaptor protein that, upon phosphorylation by the MET receptor, provides extra binding sites 
for SHC, PI3K, SHP2, CRK, PLCγ1 and p120 Ras-GTPase-activating protein (p120-Ras-
GAP)43, 44, 49, 50, 51, 52, 53. The association between MET and GAB1 occurs directly, through a unique 
13-amino-acid MET binding site (MBS) on GAB1, and indirectly, through MET-bound GRB2 
(Refs 51,54). Hence, many transducers participate in MET signalling through multiple interactions 
with the receptor, with the GAB1 scaffolding adaptor or with both (Fig. 1a). 
In tumours, intensification of MET signals is also favoured by receptor interaction with the α6β4 
integrin. MET activation leads to phosphorylation of the β4-subunit cytoplasmic domain (at three 
tyrosine residues that are embedded in consensus sequences) and this is required for the 
recruitment of SHC, PI3K and SHP2 (Refs 55,56,57,58). By accomplishing this function, GAB1 and 
the α6β4 integrin behave as supplementary docking platforms for the localized recruitment of 
additional transducers that synergize with those directly bound to MET (Fig. 1a). This mechanism 
allows signal amplification at the MET-proximal level, which in turn secures potent and enduring 
activation of downstream transducers. 
 
CD44 links MET to the cytoskeleton. Another protein that cooperates with MET in normal and 
transformed epithelial cells is CD44, a transmembrane cell adhesion molecule that functions as a 
linker between the extracellular matrix and the intracellular actin cytoskeleton59. Members of the 
CD44 family differ in their extracellular domain by the insertion of variable regions through 
alternative splicing, which gives rise to numerous variant isoforms (CD44v1–CD44v10)59. The 
CD44 isoform containing the v6 sequence participates in MET signalling by a twofold mechanism: 
the extracellular domain is required for the organization of a ternary complex between MET, HGF 
and CD44 and for the subsequent activation of MET60. The cytoplasmic tail is necessary for signal 
transfer from active MET to Ras61. Specifically, upon MET activation, the intracellular domain of 
CD44v6 drives the assembly of a sub-membraneous network that includes the cytoplasmic region 
of MET, GRB2, F-actin, ezrin, radixin and moesin (ERM) proteins (which connect actin 
microfilaments to CD44) and the guanine nucleotide exchange factor son of sevenless (SOS). This 
network allows for efficient activation of Ras by SOS (Fig. 1b). 
In endothelial cells, the v10-containing isoform of CD44 seems to be essential for the partitioning of 
MET into detergent-insoluble, caveolin-enriched microdomains together with T-lymphoma invasion 
and metastasis-inducing protein 1 (TIAM1; a RAC1 exchange factor), cortactin (an actin 
cytoskeletal regulator) and dynamin 2 (a vesicular regulator)62. Thus, when MET collaborates with 
CD44, signal transduction is assisted by its structural and topographical regulation at the inner side 
of the plasma membrane rather than by its functional interaction with signalling amplifiers. The 
reasons why only some CD44 variants contribute to MET signalling remain unclear. 
Semaphorins activate MET in an HGF-independent manner. The extracellular domain of MET 
exhibits structural homology with the semaphorins and plexins, a broad family of ligand–receptor 
pairs that are endowed with either attractive or repulsive function in different tissues (Box 1). In 
particular, MET and class B plexins share a highly homologous Sema domain, which forms a 
seven-bladed β-propeller that supports multiple interactions between MET and some class B 
plexins. When oligomerized with plexins, MET can be activated by semaphorins in an HGF-
independent manner, leading to stimulation of MET downstream effectors and execution of MET-
dependent biological responses63, 64, 65 (Fig. 1c). This partnership expands the complement of 
soluble factors that exert biological activity on MET-expressing cells and specifies the quality of 
cellular outcomes: cells that co-express MET and plexins react to either HGF or semaphorins by 
acquisition of invasive ability, which is a typical MET-dependent effect; by contrast, cells that 
express only plexins respond to semaphorins by arresting migration and inducing cellular collapse, 
which is a plexin-specific repulsive function66. 
 
Major MET-regulated signalling pathways 
MET-dependent signals are organized in pathways that transmit biochemical information from the 
cell membrane (where MET resides) to the nucleus (where modulation of gene expression occurs). 
As described above, the receptor-associated signalling apparatus, including scaffolding adaptors 
and surface signal modifiers, is somehow unique to MET. Conversely, the downstream transducers 
are stereotypical signalling modules that are shared among different tyrosine kinase receptors. The 
prominent examples of these biochemical pathways will now be discussed. 
 
The MAPK cascades. The subfamilies of MAPKs feature a characteristic phospho-relay system in 
which a series of three protein kinases (MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) 
and MAPK) phosphorylate and activate one another67. The ERKs are mainly triggered by tyrosine 
kinase-dependent stimulation of Ras. MET activates Ras through the GRB2–SOS complex, which 
can interact directly with the multifunctional docking site in the C-terminal tail of MET or can be 
associated indirectly through the SHC adaptor protein37,45. Another route leading to Ras–ERK 
activation involves the tyrosine phosphatase SHP2, which dephosphorylates the p120-Ras-GAP 
binding site on GAB1; this impedes the recruitment of p120-Ras-GAP, which usually deactivates 
Ras, to promote Ras activation44,53 (Fig. 2a). In the active, GTP-bound state, Ras attracts the 
Ser/Thr kinase Raf through its effector loop. This association modifies the three-dimensional 
configuration of Raf, which acquires signalling activity and proceeds to phosphorylate and thereby 
activate MAPK/ERK kinase 1 (MEK1; also known as MAPKK1) or MEK2 (also known as 
MAPKK2), the intermediate kinases of the system. In turn, MEK1 and MEK2 phosphorylate ERK1 
and ERK2, the final effectors of the cascade. Active ERKs translocate to the nucleus, where they 
phosphorylate and stabilize several transcription factors that are involved in the early phases of the 
G1–S cell cycle transition. MET-dependent activation of the Ras–ERK cascade can be decreased 
by molecules that are involved in organogenesis and tissue repair, such as the membrane receptor 
Notch and the intracellular modulator Sprouty68, 69. Interestingly, MET is able to transcriptionally 
upregulate both Sprouty and the Notch ligand Delta, suggesting a mechanism of counter-feedback 
whereby MET induces negative regulators of its own signalling, possibly to fine-tune the restricted 
execution of biological outputs in space and time. How the Delta–Notch system and Sprouty impair 
MET-triggered stimulation of the Ras–ERK pathway remains to be characterized. 
 
As well as the ERKs, MET is able to activate the JNK and p38 MAPKs. For both families, the first 
MAPKKK components of the cascade (MAPKKK1–MAPKKK4; also known as MEK kinase 1 
(MEKK1)–MEKK4) are usually stimulated by Rac, a small GTPase that is switched on by a Ras–
PI3K-mediated pathway. MEKK-dependent phosphorylation of MEK4 and MEK7 leads to activation 
of JNK1, JNK2 and JNK3, whereas phosphorylation of MEK3 and MEK6 leads to activation of 
p38α, p38β, p38γ and p38δ (Fig. 2a). Following MET-dependent stimulation, the JNKs and p38s 
control a range of cellular processes as diverse as cell proliferation, differentiation, transformation 
and apoptosis70, 71, 72, 73, 74. 
 
The PI3K–Akt axis. PI3K can be activated directly by MET and/or indirectly by Ras, the activation 
of which can also be mediated by MET (see above)37. PI3K activation results in the formation of 
phosphatidylinositol-3,4,5-triphosphate, which tethers pleckstrin homology domain (PH domain)-
containing molecules, such as the Ser/Thr kinase Akt, to the plasma membrane. Akt is then able to 
suppress apoptosis through inactivation of the pro-apoptotic protein BCL-2 antagonist of cell death 
(BAD) and activation of the E3 ubiquitin-protein ligase MDM2, which promotes the degradation of 
the pro-apoptotic protein p53. Moreover, Akt inactivates glycogen synthase kinase 3β (GSK3β), 
which antagonizes the expression of positive cell cycle regulators such as Myc and cyclin D1, and 
activates mammalian target of rapamycin (mTOR), which stimulates protein synthesis and physical 
cell enlargement (Fig. 2b). 
 
The STAT pathway. Trans-phosphorylation of the docking site of MET leads to the association of 
STATs — namely, STAT3 — with its tail47, 48. This docking event is followed by MET-dependent 
tyrosine phosphorylation of STAT3, which causes STATs to dissociate from the receptors and 
homodimerize through their SH2 domains. Eventually, STAT dimers translocate to the nucleus, 
where they operate as transcription factors to regulate the expression of several genes that are 
implicated in cell proliferation or differentiation (Fig. 2c). 
 
The IκBα–NF-κB complex. The NF-κB system comprises a family of transcription factors that are 
held inactive in the cytoplasm by a family of inhibitory proteins known as IκBs75. These inhibitors 
are ubiquitylated and degraded by a phosphorylation event that is triggered by the IκB kinase 
(IKK). In response to MET, IKK activation is mediated by the PI3K–Akt pathway and Src as 
signalling intermediates, but the direct distal effectors of IKK stimulation are unknown76. IKK-
induced destruction of IκBs leads to the release of NF-κB, which translocates to the nucleus to 
stimulate the transcription of various genes, including mitogenic and anti-apoptotic 
regulators76, 77 (Fig. 2d). 
 
Regulation of MET signalling 
It is well established that signal transduction pathways that are downstream of tyrosine kinase 
receptors are modulated not only by the identities of protein–protein interactions but also by the 
colocalization of signal transducers in membrane domains or, more broadly, in organelles and 
vesicles78. This notion has been recently applied to MET: the prevailing view that the activated 
receptor recruits signalling effectors at the plasma membrane, which in turn stimulate diffusible 
intermediates in the cytosol, has now been expanded by the finding that MET signals can also 
emanate from endosomal compartments. Moreover, the levels of MET expression at the cell 
surface are finely tuned by other spatially restricted events, including extracellular shedding, 
intracellular cleavage and ubiquitin-mediated degradation. All of these processes regulate the 
strength of MET activation and the ensuing robustness of MET-dependent signals. 
 
MET internalization can promote signalling. Following ligand binding, MET is rapidly 
internalized by clathrin-mediated endocytosis and becomes recruited to peripheral early 
endosomes79. Here, MET triggers the sustained activation of ERKs, which are then relocated 
to focal complexes, where they mediate HGF-induced cell migration (probably by phosphorylating 
paxillin and other focal adhesion targets80). A crucial regulator of this endosomal signal 
compartmentalization, and the consequent transfer of ERK to adhesion sites, is protein kinase Cɛ 
(PKCɛ) (Fig. 3a). RNA interference-mediated silencing of PKCɛ negatively influences the 
recruitment of ERK1 and ERK2 to focal adhesions81, possibly by reducing the delivery of ERK–
integrin complexes to the plasma membrane82. 
 
From the peripheral endosomes, MET traffics along the microtubule network and accumulates in a 
nondegradative perinuclear endomembrane compartment through a process that is promoted by 
PKCα81, 83 (Fig. 3b). This juxtanuclear delivery of MET is required for the optimal activation and 
nuclear translocation of STAT3 (Ref. 84). MET-triggered phosphorylation of STAT3 at the plasma 
membrane or early endosomes is likely to be below the threshold for nuclear uptake owing to the 
intense local activity of phosphotyrosine phosphatases that dissipate STAT3 signal intensity during 
protein diffusion. Conversely, post-endocytic trafficking to the perinuclear compartment brings 
active MET into close proximity to the nucleus, which shields STAT3 against phosphatase activity 
and allows its nuclear accumulation (Fig. 3b). 
 
MET internalization can inhibit signalling. Although internalized receptors may remain able to 
signal in peripheral and perinuclear compartments, the endocytosis of ligand-activated receptors 
and their subsequent degradation in the lysosomal compartment remains the major determinant of 
receptor desensitization and signal restraint85. Prompt sequestration of the activated receptor into 
invaginating pits, and its endosomal sorting for degradation, precludes prolonged signal emission 
and ensures faithful application of physiological responses. 
Trafficking to the lysosomes is triggered by ligand-induced activation of MET, and requires the 
function of casitas B-lineage lymphoma (CBL), an E3 ubiquitin-protein ligase that is recruited to a 
juxtamembrane phosphotyrosine residue in the active receptor (Tyr1003)86(Fig. 3c). This leads to 
MET being monoubiquitylated at multiple sites87, which enables its recognition by endocytic 
adaptors that contain ubiquitin-binding domains, its sorting into clathrin-coated areas at the cell 
surface and its delivery to the endosomal network. From these sorting endosomes, MET 
accumulates on the limiting and internal membranes ofmultivesicular bodies. This terminates 
signalling by sequestering MET from the cytosol and preventing it being recycled by the plasma 
membrane. Finally, the multivesicular bodies fuse with the lysosomes and MET undergoes 
proteolytic demolition88, 89. Seemingly active MET is not polyubiquitylated, and is therefore unlikely 
to be targeted for degradation by theproteasome87; however, proteasomal destruction of MET can 
occur in an ubiquitin-independent manner (see below). 
CBL also attracts — through the scaffold molecule CBL-interacting protein 85 (CIN85; also known 
as SH3KBP1) — endophilins, a family of proteins that assist the negative curvature, invagination 
and scission of the planar plasma membrane during the early phases of endocytosis90. Therefore, 
CBL promotes the physical internalization of MET while tagging it for lysosomal degradation91 (Fig. 
3c). Sustained association of CBL with active MET is favoured by decorin, an extracellular 
proteoglycan that binds directly to MET with high affinity and acts as an antagonistic ligand by 
stimulating receptor activation and, immediately thereafter, receptor downmodulation92. 
What skews the MET fate towards degradation rather than signalling remains unknown. In the 
case of the epidermal growth factor (EGF) receptor, it has been suggested that endosomal 
signalling predominates under conditions of scarce ligand, whereas the degradative pathway is 
favoured when abundant ligand is present93. A similar scenario might also apply to MET but a 
formal demonstration of such a mechanism has not been provided so far. 
 
Regulated proteolysis of MET. Downregulation of MET signalling also involves sequential 
proteolytic cleavages. The first step is a disintegrin and metalloprotease (ADAM)-mediated release 
(known as shedding) of the extracellular domain, which generates a soluble N-terminal fragment 
and a membrane-anchored cytoplasmic tail. Then, the surface-associated cytoplasmic remnant 
undergoes regulated proteolysis by γ-secretase, which yields a labile intracellular portion that is 
rapidly cleared by proteasome-mediated degradation94 (Fig. 3d). 
Unlike CBL-mediated endosomal degradation, regulated proteolysis of MET is ligand- and 
ubiquitin-independent and does not require the kinase activity of the receptor: the mechanism 
occurs basally and affords MET signalling with chronic, low-grade attenuation under steady-state 
conditions. The shedding of MET that is catalysed by ADAM metalloproteases can be acutely 
enhanced by various agents such as phorbol esters, suramin, lysophosphatidic acid and 
monoclonal antibodies (mAbs) against the MET ectodomain94, 95, 96, 97, 98, 99, 100, 101, 102. Importantly, 
the extracellular shedding of MET not only decreases the number of receptor molecules on the cell 
surface but also generates a decoy moiety that interacts with both HGF (by sequestering the 
ligand) and full-length MET (by impairing dimerization and transactivation of the native receptor) to 
further inhibit MET signalling103, 104. Therefore, the use of targeted agents — such as mAbs, which 
increase MET shedding from the cell surface — could have a great therapeutic effect on cancers 
by reducing MET signalling. 
 
MET signalling in development and disease 
To secure output production and to increase functional versatility in the face of recurring 
perturbations, tyrosine kinase receptors often expand and diversify individual components of their 
downstream signalling networks, degenerate connections and duplicate entire modules of protein–
protein interactions. Signal redundancy, reciprocal signal reinforcement and feedback loops are 
stereotypical aspects of signal transduction105. Because of this, extracting functional information 
from the dissection of individual signalling axes might be judged to be simplistic, if not futile. Signal 
compensation by other transducers that have overlapping functions must be considered. However, 
in the case of MET, different cell- and tissue-specific activities seem to be fulfilled by dedicated 
signalling cascades, with some transducers dominating over others depending on context, timing 
and biological complexity (Table 1). Here, we outline a number of genetic and pharmacologic 
studies that have contributed to this knowledge. The coverage is purposefully not exhaustive: we 
will limit our attention to those settings in which a more documented connection between signals 
and phenotypes has been provided, as well as to those for which information has become 
available only recently. 
 
 
Embryonic development. During development, HGF and MET convey essential signals for the 
growth and survival of hepatocytes and placental trophoblast cells. In Hgf- or Met-null embryos, the 
liver is considerably reduced in size and the placental labyrinth is severely 
hypomorphic106, 107, 108 (Fig. 4). This hypomorphic phenotype eventually leads to deathin 
utero owing to compromised exchange of oxygen and nutrients between maternal and fetal blood. 
The HGF–MET system also has a decisive role in the proliferation and motility of long-range 
migrating muscle progenitors. These myogenic precursors delaminate from the dermomyotome, a 
structure in the dorsolateral region of somites, and travel to the limbs, tongue and diaphragm, 
where they differentiate to form a subset of the hypaxial muscles109. Ablation of 
the Hgf or Met genes results in complete absence of this specific muscle type, leaving all other 
muscle groups unaffected104, 105, 106. Finally, disruption of HGF–MET function affects the proper 
wiring of the nervous system, leading to reduced survival of sensory and sympathetic neurons as 
well as impaired outgrowth and fasciculation (axon bundling) of certain motor nerves110, 111, 112. 
 
 
Using genetic knock-in approaches, several studies have addressed the physiological significance 
of the different signalling pathways that are regulated by MET in the whole organism. Specificity-
switch mutants, in which the MET multifunctional docking site has been converted into an optimal 
binding motif for PI3K, Src or GRB2, exhibit a rescue of defined phenotypes (when compared 
with Met-null animals) in line with the effectors that are recruited. Mice in which MET exclusively 
associates with GRB2 are viable, fertile and apparently normal — indicating that GRB2 is sufficient 
to recruit all of the necessary downstream effectors of MET — whereas mutants with dedicated 
stimulation of Src or PI3K are embryonic lethal. However, although incompatible with survival, 
individual activation of Src is sufficient to restore proliferation of placental trophoblasts and 
myoblasts, and selective activation of PI3K is sufficient to promote axon outgrowth and branching 
of specific motor nerves113. Together, these findings suggest that MET-mediated developmental 
events are accomplished by qualitatively different signals that are endowed with a tissue-specific 
activity. 
The defects that are observed in Hgf and Met knockout embryos are phenocopied in Gab1-null 
mice — albeit in a slightly attenuated form — indicating that GAB1 has an essential role in MET-
based signal transduction pathways114 (Fig. 4). As mentioned above, GAB1 associates with MET 
directly, through a specific MBS, and indirectly, through the GRB2 adaptor51, 54. The mechanism of 
recruitment of GAB1 to MET influences biological outcomes in vivo in a tissue-specific manner: 
both direct and indirect interactions with MET are necessary for functional MET signalling during 
liver and placenta formation, whereas either the GRB2 binding site or the MBS, but not both, are 
required for limb muscle development115. Similar to those observed for MET, interactions of GAB1 
with specific downstream effectors control distinct developmental processes. The association 
between GAB1 and PI3K seems to be essential for EGF receptor-mediated embryonic eyelid 
closure but this association is not involved in MET-regulated organogenesis113. MET signalling in 
embryonic development is mainly channelled by the GAB1–SHP2 interaction; indeed, GAB1 
mutants that are unable to bind SHP2 phenotypically copy Met-null mutants, with defects such as a 
thin placental labyrinth layer (Fig. 4) and impaired migration of muscle precursors115. Again, we can 
conclude that the biological responses elicited by GAB1, like those elicited by MET, have different 
signal requirements in different tissues during embryonic development. 
 
Organ regeneration. The signalling mechanisms that mediate MET-driven tissue patterning during 
organ regeneration have been studied both in vitro, by performing morphogenetic assays under 
three-dimensional culture conditions, and in vivo, using Cre–loxP-mediated conditional deletion of 
MET in selected tissues. 
When embedded in a collagen matrix, normal epithelial cells proliferate and assemble into 
spheroids, which feature a centrally localized, hollow lumen, surrounded by polarized cells116. HGF 
causes spheroids to form elongated tubules in a stepwise sequence of biological events117. First, 
cells undergo a partial epithelial–mesenchymal transition (EMT), which involves the transformation 
of tightly packed elements into invasive, spindle-shaped cells that emit long cytoplasmic extensions 
in the surrounding matrix. Then, these extensions develop into single-file chains, which must resist 
anoikis to lengthen and thicken. Ultimately, cells redifferentiate: they restore polarity and turn into 
solid cords that become mature tubules by the progressive formation of a continuous lumen. At the 
signalling level, the series of events required for HGF-dependent tubule formation has been 
dissected. As a whole, this process requires the integrity of the STAT3 and NF-κB pathways47, 77. 
The initial EMT relies on hypersustained activation of the Raf–MEK–ERK pathway, which, as 
discussed earlier, is triggered by the association of active MET-bound GAB1 with the tyrosine 
phosphatase SHP2 (Refs 44,53,118,119). Cell survival is promoted by transcription factors of the 
Snail family120. The later phases of epithelial tubulogenesis entail the activity of matrix 
metalloproteases (MMPs), which, albeit dispensable for the early formation of extensions and 
chains, seem to be necessary to produce cords and hollow tubules118. HGF has an important role 
in the regulation of the functions of MMPs by enhancing the transcriptional levels of a large number 
of MMPs as well as those of several proteases that convert the precursor forms of MMPs into 
active enzymes121, 122, 123. 
In vivo, MET function is particularly important for the regeneration of the liver and the kidney in 
response to both acute and chronic insults. Production of HGF increases steeply following liver 
damage, and the ensuing activation of MET in hepatocytes provides strong mitogenic and anti-
apoptotic stimuli for organ repair14, 15, 124. Accordingly, conditional deletion of MET in the liver 
results in impaired organ reconstitution after toxic insult and hepatectomy125, 126 (Fig. 4). In these 
mutant mice, phosphorylation of ERK1 and ERK2 is lost and there is a delay in the timing of 
maximal activation of Akt that occurs after hepatic injury. The proliferation defect is reflected by low 
transcriptional induction of cyclins and enhanced expression of the cyclin-dependent kinase (CDK) 
inhibitor p21 (also known as CIP1 and WAF1)126. An analogous phenotype of compromised hepatic 
regeneration is also seen in mice with liver-specific ablation of GAB1 or SHP2 (Ref. 127), further 
pointing to a crucial role for GAB1–SHP2 signalling in MET-driven outcomes (Fig. 4). 
MET also displays a similar protective activity in the kidney. HGF induces intense proliferative and 
anti-apoptotic responses in renal epithelial cells by activating Ras-dependent mitogenic signals, the 
PI3K–Akt pro-survival pathway and, subsequently, the transcriptional upregulation of the anti-
apoptotic effectors B-cell lymphoma-extra large (BCL-XL) and BCL-2 (Ref. 128). This powerful 
reno-protective activity prevents acute renal failure due to tubular necrosis and accelerates kidney 
regeneration. 
In the liver and the kidney, persistent damage leads to a severe fibrotic evolution that is sustained 
by overproduction of TGFβ, which instructs interstitial myofibroblasts to deposit copious amounts 
of extracellular matrix129. HGF acts as a powerful anti-fibrotic agent by antagonizing TGFβ 
fibrogenic responses in different ways, from transcriptional downmodulation of TFGβ130 to ERK-
mediated inhibition of SMADs131, 132, the cardinal transcriptional effectors of TGFβ signalling. At 
least in the liver, fibrosis is further reduced by an atypical pro-apoptotic effect of HGF on 
myofibroblasts133 (Box 2). 
Epithelial cells also exploit the trophic properties of the HGF–MET system during wound healing. 
At the wound edges, marginal keratinocytes form the so-called hyperproliferative epithelium, which 
undergoes rounds of cell division to provide fresh elements that migrate over the provisional matrix 
of the injured dermis and repopulate the wounded area134. Keratinocytes from mutant mice with 
conditional deletion of MET in the epidermis are unable to contribute to the generation of the 
hyperproliferative epithelium in vivo135. In vitro, during the closure of scratch wounds, HGF is 
necessary to re-orient keratinocytes, so that focal adhesion components, actin stress fibres and the 
plus ends of microtubules point towards the wound edges as a prelude for productive cell 
locomotion. Moreover, HGF fosters the proliferation and migration of epithelial cells into the de-
epithelialized zone. The major signalling effectors that mediate these processes are GAB1, Akt, 
ERK1 and ERK2, as well as p21-activated kinase 1 (PAK1) and PAK2, targets of RhoA that control 
actin polymerization and protrusion formation135. 
 
Cancer growth and metastasis. In most tumours, MET is transcriptionally induced by hypoxia 
and inflammatory cytokines or pro-angiogenic factors that are abundant in the reactive stroma of 
full-blown tumours34, 136. Hence, MET activation is a late event that aggravates the intrinsic 
malignant properties of already transformed cells by conveying proliferative, anti-apoptotic and pro-
migratory signals (a biological situation that our group calls 'oncogene expedience')23. 
Congruent with the view that invasive cancer cells resume behavioural programmes that are 
normally operative during embryogenesis and in damaged tissues, MET-driven exacerbation of 
cancer progression involves stimulation of all the signalling pathways that are known to mediate 
the several aspects of MET physiological responses in development and adult life. The contribution 
of specific signals to MET activity in tumours has been partially dissected through the manipulation 
of the consensus sequences that mediate the recruitment of distinct transducers. By converting the 
multifunctional docking site of an oncogenic mutant of MET into preferential binding motifs for 
GRB2 or PI3K, it was demonstrated that Ras signals are primarily involved in MET-triggered cell 
proliferation, whereas PI3K recruitment is required for the induction of cell motility and invasion; 
however, a fully metastatic phenotype can be recapitulated only when both effectors are 
concomitantly associated with MET137, 138. Thus, combined activation of multiple pathways is 
necessary to instruct the full execution of MET-dependent invasive growth in cancer cells. 
However, blocking a single network node is sufficient to perturb cellular responses, indicating that 
the targeted inhibition of a specific signalling pathway cannot be compensated for by other, still 
active, regulatory tiers. This is in line with the well-established observation that obstruction of 
individual MET-dependent pathways adversely affects tumour growth, survival and migration in 
various cancer cell types and under different experimental settings37, 48, 50, 56, 57, 58,70, 71, 72, 76, 139. For 
example, the integrity of JNK- and p38-dependent signals is required for MET-stimulated 
proliferation and anchorage-independent growth in MET-transformed fibroblasts and melanoma 
cells70, 71, 72, and STAT3 signalling and NF-κB activity are necessary for MET-induced onset of 
leiomyosarcomas and for the survival of prostate cancer cells, respectively48, 76. 
The notion that inhibiting a single transducer will suffice to revert or impair the biological phenotype 
induced by MET activation has strong implications. If there is no redundancy in the many signalling 
networks regulated by MET, this implicates that targeting any of these pathways would hamper 
one or more aspects of MET-driven cancer progression, which could pave the way for the 
development of several therapeutic strategies together with, or as an alternative to, the selective 
inhibition of MET. However, recent data suggest that this is unlikely to be the case. In a limited 
number of tumour cells featuring genetic lesions of MET — caused by gene amplification and, 
possibly, point mutations23, 140, 141 — receptor hyperactivation is inherent in the cancer's natural 
history and is required to maintain the transformed phenotype: these cells are dependent on the 
persistent activity of MET for their relentless proliferation (a situation known as 'oncogene 
addiction')142, 143. In this scenario, MET blockade affects a limited subset of MET downstream 
signals: many of the pathways controlling MET-driven responses — including STATs, JNK, p38 
and NF-κB — remain active or exhibit scant responses, and only a restricted complement of Ras 
and PI3K transducers and transcriptional effectors is neutralized144, 145, 146. Of note, a similar 
response to oncogene inactivation also occurs in cells that depend on the EGF receptor for their 
growth and survival, suggesting that cells that are 'addicted' to oncogenic tyrosine kinase receptors 
may develop common mechanisms to sustain malignancy and therefore may be susceptible to 
similar therapeutic interventions144, 145. 
The mechanisms that are responsible for this kind of selectivity have not been elucidated, but they 
could rely on feedback effects that are hard-wired into oncogene-addicted tumours. In the case of 
the EGF receptor, transcriptional induction of the dual specificity phosphatases (DUSPs), which 
are negative regulators of MAPK activity, has been proposed as a crucial step in modulating 
receptor signalling outputs147. Interestingly, DUSPs exert a promiscuous phosphatase activity on 
multiple members of the MAPK family148. One could speculate that an imbalance in substrate 
dephosphorylation might lead to the silencing of some MAPK components while leaving others 
relatively unaffected. 
Intrinsic addiction to MET is characterized by high steady-state signalling due to chronic receptor 
activation, which is the consequence of a fixed and transmissible genetic alteration; in this setting, 
the reliance of tumours on the continued activity of MET seems to be governed by a small, self-
sufficient group of signal transducers. Conversely, the activation state of MET in the context of 
oncogene expedience is dynamic because it mainly depends on the hectic and reversible 
environmental conditions that are typical of cancer; in this situation, MET-regulated outcomes are 
controlled by multiple, non-redundant signalling crosstalks. This implies that oncogene addiction 
and oncogene expedience should be considered as separate entities when managing therapeutic 





Embryonic morphogenesis, organ regeneration and cancer invasion are all facets of a common 
theme in which MET and MET signals have fundamental roles. Although the regulatory molecules 
are the same and the biological outcomes share unifying principles, the precise mechanisms that 
dictate the final execution of one or another response are far from being elucidated. The regulation 
of the different outcomes of MET activation, as well as the definition of their biological specificity, 
could depend on signal modifiers that are endowed with a tissue-restricted distribution (including, 
as recently demonstrated, microRNAs149,150, 151, 152, 153) or on dedicated protein interaction networks, 
and could be further tuned by transcriptional modulation. 
The ongoing development of new technologies is certainly one prerequisite for unravelling the 
complexity of these issues. Cell- and context-dependent signal modulators can be now identified 
by using genome-wide functional screens; higher details in regulatory protein–protein interactions 
can be achieved by using mass spectrometry; and, finally, information on the presence of positive 
or negative signalling feedback loops, which are likely to enforce or attenuate MET biochemical 
outputs, can be extracted from gene expression profiling. The long catalogues of hits pinpointed by 
such 'omics' efforts can be prioritized by using bioinformatics and challenged by using high-
throughput platforms for biological validation. 
Gathering this kind of knowledge has important medical relevance. Due to the ability of MET to 
support organ repair and contrast fibrotic evolution, agents that are endowed with agonistic activity 
are currently being tested in a number of early-phase clinical trials. From an opposite perspective, 
several MET inhibitors are being evaluated for their efficacy in blocking the growth and progression 
of various tumour types23. Most anti-cancer therapies are accompanied by drug-induced toxicity 
that could be relieved by triggering MET regenerative signals in the damaged organs; ironically, 
this approach is hindered by the reasonable concern that systemic delivery of MET-activating 
compounds in cancer patients would promote the spread of neoplastic cells and awaken dormant 
metastases154. Even more insidiously, MET-driven stimulation of growth and survival signals might 
cause the progression of incipient pre-malignant clones to full-blown malignancy in apparently 
healthy individuals. Detailed knowledge of MET-regulated signals in vivo will prove useful to 
identify the pathways that preferentially mediate the healing properties of MET and those that 
convey its lethal pro-invasive activity. If successful, this endeavour will provide momentum for 
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Hepatocyte growth factor (HGF; also known as scatter factor) is similar to plasminogen, a 
circulating zymogen that promotes the dissolution of fibrin blood clots in its active form as the 
serine protease plasmin. Both HGF and plasminogen are synthesized as a single-chain precursor 
and then converted into an active α- and β-chain heterodimer by extracellular proteases. HGF 
consists of six domains: an amino-terminal hairpin loop (HL), four kringle domains (K1–K4; each 
defined by three conserved disulphide bonds) and a serine protease homology (SPH) domain that 
lacks proteolytic activity (see the figure, part a). 
The HGF receptor MET is a single-pass heterodimer comprising an entirely extracellular α-subunit 
that is linked by a disulphide bond to a transmembrane β-subunit, which contains the intracellular 
catalytic activity (see the figure, part b). The extracellular region of MET includes three functional 
domains: the Sema domain (which is also found in the semaphorins and plexins) spans the first 
500 residues at the N terminus, encompassing the whole α-subunit and part of the β-subunit; the 
PSI domain (which is also present in the plexins, semaphorins and integrins, hence its name) 
covers approximately 50 residues and contains four conserved disulphide bonds; the residual 400 
residues connecting the PSI domain to the transmembrane helix are organized into four IPT 
(immunoglobulin-like fold shared by plexins and transcriptional factors) domains. The intracellular 
segment is composed of three portions: a juxtamembrane sequence that downregulates kinase 
activity following phosphorylation of Ser975; a catalytic region that positively modulates kinase 
activity following trans-phosphorylation of Tyr1234 and Tyr1235; and a carboxy-terminal 
multifunctional docking site that contains two docking tyrosines (Tyr1349 and Tyr1356) that are 
involved in the recruitment of several transducers and adaptors. 
HGF contains two MET binding sites that have different affinities. The high-affinity site is located in 
the α-chain and recognizes the IPT3 and IPT4 domains of MET independently of HGF processing 
and maturation155. The low-affinity site lies within the β-chain, is exposed only after HGF activation 
and interacts with the Sema domain of MET156. This latter association is depicted as a ribbon 
representation (see the figure, part c). The HGF β-chain is shown in grey and part of the 
extracellular region of MET is shown in a gradient of rainbow colours, from the N terminus (shown 
in blue) to the PSI domain (shown in red). The numbers in the centre refer to the blades, with the 
β-strands in blade 1 labelledA–D. The numbers on the edge of the Sema domain represent residue 
numbers on each side of a disordered region (dotted line). Part c modified, with permission, from 



















Despite acting as a prototypical survival factor, hepatocyte growth factor (HGF; also known as 
scatter factor) was initially named 'tumour cytotoxic factor' for its ability to elicit apoptotic responses 
in sarcoma157 and hepatoma158 cells. These results were confirmed in other cell types, including 
liver and lung myofibroblasts133, 159 and breast carcinoma cell lines160, in which HGF-induced 
apoptosis was attributed to the activation of protein kinase C and Jun amino-terminal kinase (JNK) 
or to the induction of reactive oxygen species. In ovarian cancer cells that have been treated with 
conventional chemotherapeutics, HGF enhances apoptosis through a p38 mitogen-activated 
protein kinase (MAPK)-dependent pathway73, 74. 
The mechanism by which MET (also known as HGF receptor) activation leads to opposite 
outcomes — survival by default and apoptosis in restricted cellular contexts — has been only 
partially elucidated. The extracellular domain of MET interacts with the death receptor FAS (also 
known as CD95 and TNFRSF6), which prevents FAS receptor–FAS ligand (FASL) recognition and 
FAS self-aggregation, therefore limiting apoptosis through the extrinsic pathway161(see the figure, 
part a). However, elevated HGF levels sensitize cells to FASL-mediated apoptosis161. It has been 
proposed that excessively high concentrations of HGF would titre out MET and liberate FAS from 
its association with MET, suggesting that the pro-apoptotic effects evoked by HGF in some cell 
lines could be related to a critical stoichiometry in the reciprocal amounts of HGF, MET, FAS and 
FASL. 
The intracellular domain of MET is also involved in the positive control of apoptosis. Under stress 
conditions, the MET cytoplasmic portion undergoes sequential cleavage by caspases, first at an 
aspartic acid residue in the carboxy-terminal end (Asp1374) and then at a second aspartic acid in 
the juxtamembrane portion (Asp1000) (see the figure, part b). This yields an intracellular soluble 
fragment, which is comprised of the kinase domain and triggers cell death162, 163. Notably, if stress 
induction is accompanied by HGF stimulation, caspase activation is reduced and generation of the 
intracellular pro-apoptotic fragment is prevented162. This points to the presence of a cellular 
rheostat, in which life or death are ultimately dictated by the anti-apoptotic input that is generated 
by HGF-dependent activation of MET and the pro-apoptotic input that is generated by caspase-





Figure 1. The strength, duration and versatility of signals triggered by MET (also known as HGF 
receptor) are regulated by a network of signalling amplifiers and co-receptors that physically 
associate with MET. a | Adaptor proteins that have a scaffolding function, such as GRB2-
associated-binding protein 1 (GAB1) and the α6β4 integrin, associate with MET and act as 
supplementary docking platforms for the further binding of signal transducers, thus enhancing 
signalling outputs. GAB1 interacts with MET both indirectly (through growth factor receptor-bound 
protein 2 (GRB2)) and directly. Following MET-dependent tyrosine phosphorylation, GAB1 
provides additional sites for the recruitment of Src-homology-2 domain-containing transforming 
protein (SHC), phosphoinositide 3-kinase (PI3K), SHP2 (also known as PTPN11), CRK, 
phospholipase Cγ1 (PLCγ1) and p120 Ras-GTPase-activating protein (p120). Similarly, the β4 
subunit of the α6β4 integrin directly associates with MET, which tyrosine-phosphorylates β4 and 
therefore generates extra binding sites for SHC, PI3K and SHP2. GRB2 can also associate with 
SHC that is bound to MET or α6β4 integrin. b | The extracellular domain of the v6 splice variant of 
the hyaluronan receptor CD44 (CD44v6) forms a ternary complex with MET and hepatocyte growth 
factor (HGF), an event that is necessary for MET activation. The intracellular portion of CD44v6 
links the MET cytoplasmic domain to actin microfilaments through GRB2 and intermediate ezrin, 
radixin and moesin (ERM) proteins, which facilitates MET-induced activation of Ras by the guanine 
nucleotide exchange factor son of sevenless (SOS). c | Members of the class B plexins family 
associate with MET and transactivate it in response to their semaphorin ligands (Sema), even in 
the absence of HGF, providing an alternative way to stimulate MET-driven biological responses. 
Semaphorin-dependent activation of MET also results in tyrosine phosphorylation of the plexin 
cytoplasmic domain, but the functional consequences of this event are unknown. STAT3, signal 









Figure 2. MET (also known as HGF receptor) triggers several downstream pathways. a | The mitogen-
activated protein kinase (MAPK) cascades consist of three subfamilies, each of which comprises three 
protein kinases that activate one another sequentially. The proximal elements are activated directly or 
indirectly by the Ras small GTPase, which in turn is switched on by son of sevenless (SOS) and switched off 
by GTPase activating proteins (GAPs), such as p120 Ras-GAP (p120). SOS can be activated and p120 can 
be inhibited in response to MET signalling. The terminal effectors include extracellular signal-regulated 
kinases (ERKs), Jun amino-terminal kinases (JNKs) and p38s. These translocate to the nucleus, where they 
influence the activity of various transcription factors. b | Phosphoinositide 3-kinase (PI3K) is a lipid kinase 
that associates with the multifunctional docking site of MET and catalyses the formation of 
phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3). Production of PtdIns(3,4,5)P3 creates a docking 
site for Akt. Once compartmentalized at the inner side of the plasma membrane, Akt becomes activated and 
phosphorylates several substrates involved in cell proliferation, survival and the regulation of cell size. c | 
Signal transducer and activator of transcription 3 (STAT3) monomers bind to MET through their Src-
homology-2 domain (SH2 domain) and become trans-phosphorylated. Thereafter, each STAT3 moiety 
homodimerizes, using its SH2 domain to recognize the phosphotyrosine of its partner, and translocates to 
the nucleus to operate as a transcription factor. d | In response to MET stimulation and the ensuing 
activation of PI3K- and Src-dependent pathways, nuclear factor-κB inhibitor-α kinase (IKK) is activated, and 
phosphorylates the nuclear factor-κB inhibitor-α (IκB) proteins (which are bound to nuclear factor-κB (NF-
κB)). This triggers the ubiquitin-dependent degradation of IκB, resulting in the nuclear translocation of NF-κB 
and transcription. In all diagrams, dashed lines indicate that the signalling intermediates between the two 
nodes have not been characterized in detail. BAD, BCL-2 antagonist of cell death; GAB1, GRB2-associated-
binding protein 1; GRB2, growth factor receptor-bound protein 2; GSK3β, glycogen synthase kinase 3β; 
MEK, MAPK/ERK kinase (also known as MAPKK); MEKK, MEK kinase; mTOR, mammalian target of 
rapamycin; SHC, SH2 domain-containing transforming protein. 
 
Figure 3. After being internalized from the cell surface, MET (also known as HGF receptor) can maintain a 
signalling-competent modality or can be demolished. a | The recruitment of MET into early endosomes is 
mediated by protein kinase Cɛ (PKCɛ) and favours the delivery of active extracellular signal-regulated kinase 
(ERK) to focal adhesions, where it can mediate hepatocyte growth factor (HGF; also known as scatter 
factor)-induced cell migration. b | MET sorting into non-degradative perinuclear endomembrane 
compartments is mediated by PKCα. In these compartments, the activity of phosphotyrosine phosphatases, 
which work on signal transducer and activator of transcription 3 (STAT3) to dissipate signal intensity, is low. 
This favours efficient phosphorylation of STAT3 by MET and translocation of STAT3 into the nucleus. c | 
Downregulation of active MET is initiated by MET association with casitas B-lineage lymphoma (CBL), an E3 
ubiquitin (Ub)-protein ligase that bridges MET and endocytic adaptors. CBL also associates with endophilins 
through the scaffold molecule CBL-interacting protein 85 (CIN85), which promotes changes in the plasma 
membrane that are necessary for cell surface curvature in the early phases of endocytosis. Following 
endocytosis and intermediate accumulation in multivesicular bodies, MET is subjected to lysosomal 
degradation. d | MET can also undergo sequential proteolytic cleavage at two juxtamembrane sites, one in 
the extracellular domain and the other in the intracellular domain. The first cleavage (known as shedding), 
which is carried out by a disintegrin and metalloprotease (ADAM)-like extracellular protease, generates a 
soluble extracellular 'decoy' fragment that interferes with the activity of the full-length receptor and 
sequesters the ligand. This shedding is stimulated by various agents such as phorbol esters (PMAs), 
suramin, lysophosphatidic acid (LPA) and monoclonal antibodies (mAbs) against the MET extracellular 
domain. The second cleavage is performed by γ-secretase and yields an intracellular fragment that is 
destroyed by the proteasome in an ubiquitin-independent manner. Dashed lines indicate that the signalling 




Figure 4. Mutant mice with targeted disruption of hepatocyte growth factor (HGF; also known as scatter 
factor)- or MET (also known as HGF receptor)-dependent signals show various abnormalities that are related 
to proliferative impairment. a | The liver of HGF knockout (HGF−/−) mice features severe loss of cellularity and 
enlarged sinusoids compared with that of wild-type embryos (HGF+/+ mice). Similarly, the labyrinth layer 
(delimited by dotted lines) contains fewer trophoblast cells, embryonic vessels and maternal sinuses and 
more mesenchymal cells. The junctional zone (denoted by an asterisk) lies above the labyrinth. b | An 
analogous placental defect, with a large reduction in the size of the labyrinth layer, occurs in mice with 
genetic deletion of GRB2-associated-binding protein 1 (GAB1). c | The same phenotype is also displayed in 
mice that harbour a knock-in point mutation that abolishes GAB1 interaction with SHP2 (also known as 
PTPN11) (GAB1ΔSHP2/ΔSHP2 mice). d | In adult animals, Cre–loxP-mediated conditional deletion of MET in the 
liver impairs hepatic regeneration following toxic insult, as shown by the reduction of hepatocytes 
incorporating bromo-deoxyuridine (BrdU), which indicates a decrease in proliferating hepatocytes. Larger 
necrotic areas are also evident in the liver of MET−/− mice compared with control liver (Cre-ctrl). A similar 
decrease of proliferating hepatocytes can be observed during post-hepatectomy regeneration in mice with 
liver-specific knockout of GAB1 and in mice with liver-targeted disruption of SHP2 (Ref. 127). Images in 
part a modified, with permission, from Refs 106, 107 © (1995) Macmillan Publishers Ltd. All rights reserved. 
Images in part b modified, with permission, from Ref. 114 © (2000) The Rockefeller University Press. Images 
in part c modified, with permission, from Ref. 115 © (2007) National Academy of Sciences, USA. Images in 
part d modified, with permission, from Ref. 125 © (2004) National Academy of Sciences, USA. 
